Clinical and imaging features of abdominal wall endometriomas

Effectiveness and complication rates of high intensity focused ultrasound treatment for abdominal wall endometriosis: A systematic review

In this review, a systematic literature search on the effectiveness and complication rates of ultrasound-guided and magnetic resonance-guided high-intensity focused ultrasound (USg-/MRgHIFU) for abdominal wall endometriosis (AWE) was conducted in six databases in May/June 2023. Original articles of (non)randomized trials, cohort studies, case-control studies and case series published in peer-reviewed journals were included. Of the included studies the level of evidence (LoE) and methodological quality using the ROBINS-I and IHE-QAT was assessed. Primary outcomes were non-perfused volume ratio (NPV%), lesion size, pain scores, side effects and complication rates according to Society of Interventional Radiology (SIR) guidelines. Secondary outcomes were recurrence and re-intervention rates. Seven cohort studies (one of good methodological quality) (LoE 3) on USgHIFU were included (n = 212, AWE lesions = 240-245). Six months after USgHIFU treatment, pain scores were reduced with 3.3-5.2 points (baseline: 5.1-6.8, n = 135). Self-limiting side effects were pain (85.7 % (114/133)) and swelling (34.6 % (46/133)) in the treatment area. Complications occurred in 17.7 % (32/181), all of which were minor. Recurrence occurred in 12.8 % (11/86). Three of these seven cohort studies compared USgHIFU (n = 61) with surgical excision (n = 74). Pooled results showed no significant differences in pain scores, complications (resp. 26.3 % (10/38) vs. 32.6 % (15/46) (p = 0.53)) and recurrences (resp. 4.9 % (3/61) vs. 5.4 % (4/74) (p = 0.90)). This systematic review suggests that HIFU is an effective and safe treatment option for AWE. USgHIFU treatment led to reduced pain scores and lesion size, was free of major complications and had a pooled recurrence rate of 12.8 %. Compared to surgical excision pooled results showed no significant differences in pain scores, complications and recurrences after USgHIFU. However, many of the included studies had limitations in their methodological quality and therefore the results should be interpreted with caution. Well-structured high-quality randomized controlled trials comparing HIFU to standard care should be conducted to provide more conclusive evidence.

Efficacy and safety of high-intensity focused ultrasound ablation for rectus abdominis endometriosis: a 7-year follow-up clinical study

Background

The aim of this study was to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) for the ablation of rectus abdominis endometriosis (RAE) as a noninvasive modality.

Methods

All patients diagnosed with RAE who underwent HIFU ablation were followed up for 7 years. The following demographic characteristics of the patients were collected and analyzed: lesion location, size, and number; HIFU ablation; and recurrence.

Results

HIFU ablated 65 lesions in 56 patients with a median age of 36.5±9.19 years and a median lesion volume of 8.2 cm³. The main symptom was a palpable painful mass (n=61, 93.9%), which protruded from the skin surface in 6 cases (9.23%). Ultrasound was initially scanned in all patients (n=56, 100%), while 6% (n=3) required magnetic resonance imaging (MRI) to distinguish the features and range of the masses. Ablation was completed with a median sonication time of 393 s, a treatment time of 46 min, 150 W of power, and 63,525 J of total energy to treat lesions with a median volume of 5.03 cm³. There were no severe complications during the 84-month follow-up period, except for 2 patients who experiences hematuria. The pooled recurrence rate of RAE in this cohort was 1.8% (n=1).

Conclusions

As HIFU is effective and safe and retains the integrity of the abdominal wall, it should be the preferred method for the treatment of RAE.